CTRI/2022/12/047857已完成3 期
â??A Phase III, Prospective, Randomized, Double Blind, Double Dummy, Active-Controlled, Comparative, Parallel Group, Multicentric Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Dose Combination of Dapagliflozin plus Linagliptin Tablets in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Monotherapy.â??
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 232
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male or female patients aged between 18 to 65 years (both inclusive) with diagnosis of Type 2 diabetes mellitus.
- •2. Patients along with diet and exercise control, additionally on the stable dose of Metformin >= 1000 mg/day as monotherapy for at least 6 weeks prior to screening and having inadequate glycemic control at screening defined as HbA1c levels of >= 8.0% to <= 10.0%.
- •3. Women of childbearing potential (WOCBP) must be using an acceptable method of contraception to avoid pregnancy throughout the study. WOCBP must have a negative urine pregnancy test at screening / baseline visit.
- •4. Patients with no abnormality on 12-lead ECG at screening / baseline visit.
- •5. Patient with ability to understand and provide written informed consent form, which must have been obtained prior to screening.
- •6. Patients willing to comply with the protocol requirements.
排除标准
- •1. Patients with a history of Type 1 diabetes mellitus or secondary diabetes mellitus or diabetes insipidus.
- •2. Patients with a history of metabolic acidosis or diabetic ketoacidosis.
- •3. Patients with a history of bariatric surgery or lap-band procedure within 12 months prior to screening.
- •4. Patients with Fasting Plasma Glucose (FPG) > 270 mg/dL at screening.
- •5. Patients with the Body Mass Index (BMI) >= 45.0 kg/m2 at screening.
- •6. Patients with Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 [using the Modification of Diet in Renal Disease (MDRD) equation] at screening.
- •7. Patients with clinically significant impaired hepatic function (SGOT & SGPT more than 3X the UNL and/or Total bilirubin more than 2X the UNL) at screening.
- •8. Patients taking loop diuretics within one week prior to screening or planning to take during the study.
- •9. Patients with history of taking any weight loss medications within 3 months prior to randomization.
- •10. Patients with treatment of glucocorticoids equivalent to oral Prednisolone >= 10 mg (Betamethasone >= 1.2 mg, Dexamethasone >= 1.5 mg, Hydrocortisone >= 40 mg) per day within 30 days prior to randomization; topical, nasal or inhaled corticosteroids are allowed.
- •11. Patients suffering with end-stage renal disease or on dialysis.
- •12. Patients suffering from severe urinary tract infections (e.g., urosepsis, pyelonephritis), necrotizing fasciitis of the Perineum (Fournierâ??s Gangrene), intravascular volume contraction and/or female genital mycotic infections prior to 6 months from screening.
- •13. Patients with a history of congestive heart failure defined as New York Heart Association (NYHA) class III/IV, unstable or acute congestive heart failure.
- •14. Patients with significant cardiovascular history defined as: myocardial infarction, unstable angina pectoris, transient ischemic attack, unstable or previously undiagnosed arrhythmia, cardiac surgery or revascularization (coronary angioplasty or bypass grafts), or cerebrovascular accident.
- •15. Patients with any condition (e.g., infection, trauma and surgery) which require insulin therapy at the time of screening or during the study period.
- •16. Patients with history or currently suffering with severe and disabling arthralgia.
- •17. Patients with history or currently suffering with bullous pemphigoid requiring hospitalization and taking DPP-4 inhibitors.
- •18. Patients with history of inflammatory bowel disease or intestinal ulcers or chronic enteric diseases related to digestion and absorption.
- •19. Patients with uncontrolled hypertension with sitting systolic BP >= 160 mmHg and/or diastolic BP >= 100 mmHg at screening.
- •20. Any abnormality on 12-lead ECG at screening that in the opinion of the investigator is clinically significant and is judged as potential risk for patientâ??s participation in the study.
- •21. Patients with history of hereditary QT prolongation syndrome or patients having history of Torsades de pointes.
- •22. Patients who are accepting treatments of arrhythmias.
- •23. Patients with a history of anaemia or haemoglobinopathy and/or haemoglobin < 10 g/dL for men; haemoglobin < 9 g/dL for women at screening.
- •24. Patients with known history of acute pancreatitis.
- •25. Patients with intolerance, contraindication or potential allergy/hypersensitivity to any of the ingre
研究者
相似试验
已完成
3 期
A clinical study to investigate the effect of Fexofenadine plus Montelukast Oral Suspension for the treatment of allergic rhinitis in children aged 6 to 11 yearsCTRI/2022/11/047718Synokem Pharmaceuticals Ltd196
已完成
3 期
A clinical study to assess the effectiveness and side effects of Naftifine Cream 2% in patients with fungal infection of foot.CTRI/2022/06/043131Synokem Pharmaceuticals Ltd198
已完成
3 期
A clinical study to assess the efficacy and safety of combination of Vildagliptin plus Pioglitazone Tablets in patients with diabetes.CTRI/2022/09/045148Synokem Pharmaceuticals Ltd192
已完成
3 期
A Clinical Study to Compare the Efficacy and Safety of Ozenoxacin Cream 1% w/w in patients with Secondarily Infected Traumatic Skin LesionsCTRI/2020/12/029449Om Sai Pharma Pack204
已完成
3 期
A clinical study to evaluate the efficacy and safety of tablets containing Dapagliflozin and Vildagliptin in Patients with diabetes.CTRI/2021/09/036132Exemed Pharmaceuticals270